Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients.
Jacobs TG, Waalewijn H, Houlden L, Bollen PDJ, Nanduudu A, Nambi E, Cassim H, Lugemwa A, Makumbi S, Monkiewicz LN, Shakeshaft C, Bamford A, Archary M, Musuro G, Chidziva E, Mujuru HA, Bwakura-Dangarembizi M, Chabala C, Turkova A, Gibb DM, Cotton MF, Aarnoutse R, Burger DM, Colbers A. Jacobs TG, et al. Among authors: bollen pdj. Br J Clin Pharmacol. 2024 Nov;90(11):2947-2952. doi: 10.1111/bcp.16238. Epub 2024 Sep 3. Br J Clin Pharmacol. 2024. PMID: 39228168
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ, Moore CL, Mujuru HA, Makumbi S, Kekitiinwa AR, Kaudha E, Parker A, Musoro G, Nanduudu A, Lugemwa A, Amuge P, Hakim JG, Rojo P, Giaquinto C, Colbers A, Gibb DM, Ford D, Turkova A, Burger DM; ODYSSEY trial team. Bollen PDJ, et al. Lancet HIV. 2020 Aug;7(8):e533-e544. doi: 10.1016/S2352-3018(20)30189-2. Lancet HIV. 2020. PMID: 32763217 Free PMC article. Clinical Trial.
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Waalewijn H, Chan MK, Bollen PDJ, Mujuru HA, Makumbi S, Kekitiinwa AR, Kaudha E, Sarfati T, Musoro G, Nanduudu A, Lugemwa A, Amuge P, Moore CL, Rojo P, Giaquinto C, Colbers A, Gibb DM, Ford D, Turkova A, Burger DM; ODYSSEY Trial Team. Waalewijn H, et al. Among authors: bollen pdj. Lancet HIV. 2022 May;9(5):e341-e352. doi: 10.1016/S2352-3018(21)00292-7. Epub 2022 Feb 18. Lancet HIV. 2022. PMID: 35189082 Free PMC article.
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trial Team. Turkova A, et al. Among authors: bollen pdj. Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19. Lancet HIV. 2022. PMID: 35868341 Free PMC article. Clinical Trial.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free PMC article. Clinical Trial.
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R; IMPAACT P1093, ODYSSEY (PENTA 20) Study Teams. Chandasana H, et al. Clin Pharmacokinet. 2023 Oct;62(10):1445-1459. doi: 10.1007/s40262-023-01289-5. Epub 2023 Aug 21. Clin Pharmacokinet. 2023. PMID: 37603217 Free PMC article.
Dolutegravir is not removed during hemodialysis.
Bollen PD, Rijnders BJ, Teulen MJ, Burger DM. Bollen PD, et al. AIDS. 2016 Jun 1;30(9):1490-1. doi: 10.1097/QAD.0000000000001086. AIDS. 2016. PMID: 27167013 No abstract available.
Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ, de Graaff-Teulen MJA, Schalkwijk S, van Erp NP, Burger DM. Bollen PDJ, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan 15;1105:76-84. doi: 10.1016/j.jchromb.2018.12.008. Epub 2018 Dec 10. J Chromatogr B Analyt Technol Biomed Life Sci. 2019. PMID: 30572204